Biotin-Modified Exendin Peptides for Extended In Vivo Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The short in vivo half-life of GLP-1 peptides due to rapid degradation by DPP-IV limits their therapeutic effectiveness in treating diabetes and other metabolic disorders, and existing approaches to extend their half-life often come with side effects or reduced biological activity.
Innovation Solution
Development of exendin-3 and exendin-4 derivatives modified with biotin at specific lysine residues, which are designed to increase their in vivo residence time, absorption, and maintain pharmacological properties similar to native exendin, using a method involving biotin conjugation and purification processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 peptides are used for therapy, then insulin secretion is stimulated and glucagon secretion is inhibited, but the in vivo half-life is extremely short due to rapid degradation by DPP-IV
Solution Approach 1:
The patent applies composite materials by creating a conjugate of exendin-4 with biotin and hydrophilic polymer. This composite structure combines the GLP-1 receptor agonist activity of exendin-4 with the extended circulation properties of the hydrophilic polymer, thereby extending in vivo half-life while maintaining therapeutic effectiveness. The biotin serves as a linker connecting the peptide to the polymer, creating a stable composite that resists DPP-IV degradation.
Solution Approach 2:
The patent uses biotin as an intermediary molecule to connect exendin-4 to the hydrophilic polymer. This intermediary allows the peptide to be attached to the polymer without losing its biological activity, as the biotin-exendin-4 conjugate maintains GLP-1 receptor binding capability while the polymer portion provides extended circulation time and protection from degradation.
2Duration of action of moving object
If DPP-IV inhibitors are used to prevent degradation of GLP-1, then in vivo half-life is extended, but side effects occur
Solution Approach 1:
The patent extracts the problematic DPP-IV inhibition mechanism and replaces it with a structural modification approach. Instead of using drugs that inhibit DPP-IV enzyme activity (which cause side effects), the invention modifies the exendin-4 structure itself by conjugating it with hydrophilic polymer, making the peptide resistant to degradation without interfering with DPP-IV enzyme function, thereby avoiding associated side effects.
3Duration of action of moving object
If exendin-4 is modified with biotin at specific lysine residues, then in vivo residence time is increased and absorption is improved, but the molecular structure becomes more complex
Solution Approach 1:
The patent applies local quality by modifying only specific lysine residues (at positions 12 or 27) of the exendin-4 molecule rather than altering the entire structure. This localized modification at specific sites preserves the overall peptide structure and GLP-1 receptor binding capability while adding the desired properties of extended residence time and improved absorption through biotin-polymer conjugation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biotin-modified exendin derivatives exhibit extended half-life and biological activity, minimizing side effects and effectively treating conditions like diabetes and obesity, while also inhibiting gastric and intestinal motility, with improved absorption and stability, as demonstrated by enhanced insulin secretion and glucose regulation.
Implementation Method 1
exendin-3 or exendin-4 derivatives modified with biotin
Implementation Method 2
a method involving biotin conjugation and purification processes
Data Source
AI summary
Disclosed are exendin-3 or exendin-4 derivatives modified with biotin, a preparation method thereof and a pharmaceutical composition containing the same. More specifically, disclosed are exendin-3 or exendin-4 derivatives in which the lysine residue of exedin is modified with biotin. The disclosed exendin-3 or exendin-4 derivatives modified with biotin show biological activity similar to that of native exendin and at the same time, have increased in vivo stability and are easily absorbed through the mucosa. Thus, biotin-modified exendin-3 or exendin-4 derivatives are useful for treating diseases, which can be caused by the excessive secretion of insulin, the lowering of plasma glucose, the inhibition of gastric or intestinal motility, the inhibition of gastric or intestinal emptying or the inhibition of food intake. Particularly, the biotin-modified exendin-3 or exendin-4 derivatives are useful for the treatment of diabetes, obesity and irritable bowel syndromes.